Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-03-08

Clinical Trial Update: Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM [Phase 3]

View source ↗

Summary

Phase 3 studies evaluated linagliptin as monotherapy and in combination for type 2 diabetes mellitus; results from the completed trial were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2012-03-08